Publication | Closed Access

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

Cervical Cancer ManagementMetastatic Cervical CancerCervical CancerPhase Ii TrialMedicineCancer ManagementClinical TrialsGynecologyCancer TreatmentPublic HealthThird-line TreatmentOncologyRadiation OncologyGynecology Oncology